Brief reportsLong-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia
References (8)
- et al.
Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial
Lancet
(2001) - et al.
Atherosclerotic changes of extracoronary arteries are associated with the extent of coronary atherosclerosis
Am J Cardiol
(2000) - et al.
ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness
Circulation
(2002) - et al.
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial
JAMA
(2004)
Cited by (67)
Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial
2017, Journal of Clinical LipidologyCitation Excerpt :One potential reason was that the greater use of statin therapy not only reduced atheroma volume, but also “stabilized” atherosclerotic plaques via reduced inflammation and increased collagen content,6 thus contributing to a lower baseline CIMT over time7,8 and greater challenges in producing differential CIMT and ASCVD outcomes benefits. For example, in trials using atorvastatin up to 80 mg/d, CIMT was often minimal, mitigating the potential of a lipid-altering agent to demonstrate a differential response of active treatment vs placebo.9–11 The results of these CIMT trials contrasted with the known benefits of atorvastatin demonstrated in cardiovascular outcome trials, including those in which patients were previously treated with lipid-lowering therapy.12
Changing characteristics of statin-related cIMT trials from 1988 to 2006
2016, AtherosclerosisCombination therapy in dyslipidemia: Where are we now?
2014, AtherosclerosisCitation Excerpt :This effect of atorvastatin was not evident either in studies of postmenopausal women [72,73], or in patients with FH treated with atorvastatin only in the Rating Atherosclerotic Disease Change by Imaging with a New CETP Inhibitor (RADIANCE) trial who had received substantial statin treatment prior to enrollment with a baseline CIMT of 0.68 and 0.72 mm, respectively [74]. However, in the Atorvastatin vs Simvastatin on Atherosclerosis Progression (ASAP) trial, atorvastatin 80 mg reduced CIMT in familial hypercholesterolemia (FH) patients who were untreated or not extensively treated with statins (CIMT 0.93 mm; LDL-C > 175 mg/dL) [75], although no further reduction of CIMT was seen in the 2-year extension of that study (0.89–0.90 mm) [76]. In the placebo-controlled Measuring Effects on Intima-Media Thickness: an Evaluation of Rosuvastatin (METEOR) trial, rosuvastatin was associated with a statistically significant reduction in CIMT progression over 2 years and, although the study was not powered to make safety comparisons, no notable differences were seen in CVD event rates [77].
This study was supported by Pfizer, Capelle aan de Yssel, The Netherlands.